Circulating free and low-density lipoprotein-bound GD2 can compete in vitro with neuroblastoma cells for binding therapeutic anti-GD2 antibodies
Open Access
- 26 January 2026
- journal article
- Published by Aboutscience Srl in Journal of Circulating Biomarkers
- Vol. 15 (1) , 69-77
Abstract
Introduction: GD2 is a ganglioside expressed on neuroblastoma cell membranes and shed into the circulation, where it primarily circulates bound to low-density lipoprotein (LDL). We questioned whether LDL-bound GD2 could interfere with the binding of therapeutic anti-GD2 monoclonal antibodies (like dinutuximab) to neuroblastoma cells.Methods: The GD2-expressing neuroblastoma cell line IMR5 was stained with an anti-GD2 antibody tagged with allophycocyanin (APC) at the lowest possible saturating concentration, and mean fluorescence intensity was measured by flow cytometry after in vitro exposure to GD2-LDL or free GD2 at multiple concentrations. Control experiments assessed the ability of GD2-expressing and GD2-non-expressing cells to compete for anti-GD2-APC antibodies with IMR5 cells.Results: Free and LDL-bound GD2 reduced anti-GD2-APC antibodies’ binding to IMR5 cells in vitro in a concentration-dependent manner. At physiologically relevant concentrations, LDL-bound GD2 blocked antibody binding to IMR5 to a greater extent than free GD2, including at 100 nM, a concentration below median GD2 concentrations in patients with high-risk neuroblastoma. At higher concentrations, LDL-bound GD2 inhibited antibody binding to IMR5 by up to 92.6%, whereas the same concentration of free GD2 only decreased antibody binding by 56.6%Conclusions: At concentrations found in patients with high-risk neuroblastoma, both free GD2 and LDL-bound GD2 blocked anti-GD2 antibody binding to neuroblastoma cells. These data suggest that circulating GD2-LDL could impact the efficacy of therapeutic anti-GD2 antibodies administered to patients with a high disease burden during induction therapy or at relapse and may have therapeutic implications for GD2-directed adoptive cellular therapies.Keywords
Funding Information
- Alex's Lemonade Stand Foundation for Childhood Cancer (Centers for Excellence in Developmental Therapeutics)
- National Center for Advancing Translational Sciences (TL1TR001880)
This publication has 22 references indexed in Scilit:
- TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapyOncoImmunology, 2022
- Age-dependent reference intervals in children for the disialoganglioside, GD2, a circulating tumor biomarker for the childhood cancer, neuroblastomaClinical Biochemistry, 2022
- Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLCNew England Journal of Medicine, 2020
- The ganglioside GD2 as a circulating tumor biomarker for neuroblastomaPediatric Blood & Cancer, 2019
- Humanized 3F8 Anti-GD2Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant NeuroblastomaJAMA Oncology, 2018
- Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trialThe Lancet Oncology, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastomaCancer Chemotherapy and Pharmacology, 2014
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for NeuroblastomaNew England Journal of Medicine, 2010
- Shedding of GD2 ganglioside by human neuroblastomaInternational Journal of Cancer, 1987